



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## **EXPRESSION ANALYSIS ENTERS AGREEMENT WITH GENEGO TO PROVIDE FUNCTIONAL ANALYSIS SERVICES USING 1-2-3 WORKFLOW**

**St. Joseph, MI. July 10th 2007** –GeneGo, Inc., the leading systems biology tools company, announced today that Expression Analysis, Inc. will be providing functional analysis (pathways and networks) add-on services to their customers. Expression Analysis is the leading microarray services and solutions provider for clinical trials customers. GeneGo’s “1-2-3 Workflow” automatically uploads and normalizes genomics data, compares multiple expression datasets to identify their common, similar and unique components, conducts enrichment analysis in multiple knowledge ontologies such as diseases, canonical pathways and functional processes and then calculates the most relevant networks and the focal hub proteins. The end product is a comprehensive Word report which will be supplied as an option with microarray assays delivered by Expression Analysis.

“We are very pleased to be working with Expression Analysis as they offer excellent microarray services using standardized protocols for Affymetrix GeneChip® brand technology,” said Julie Bryant, GeneGo’s VP of Business Development. “1-2-3 workflow is an ideal vehicle for value-add functional analysis for OMICs service organizations as it provides a very comprehensive report quickly and in an easy-to-understand Word format at a reasonable cost.”

Expression Analysis is committed to being a full-service genomics provider,” said Steve McPhail, CEO and President of Expression Analysis, Inc. “Our standard microarray service includes statistical analyses to identify differentially expressed genes. However, some investigators request help translating the gene list into functional relationships. The GeneGo service will provide this assistance using an established software product. We see it as a natural partnership for both companies and a definite value for our clients.”

### **About GeneGo, Inc.**

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of

different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.3™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 2.0™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at [www.genego.com](http://www.genego.com).

**MetaCore™, MetaBase™, MetaDrug™, MetaLink™, MetaDiscovery™, MetaTox™ and MetaMiner™, 1-2-3 Workflow™ are trademarks of GeneGo, Inc.**

#### **About Expression Analysis, Inc.**

Expression Analysis, Inc. (<http://www.expressionanalysis.com>) is the industry's leading provider of microarray-based genomic services for clinical trials. Specializing in gene expression and genotyping assays on Affymetrix GeneChip® microarrays, the company also provides complementary services using Illumina, Luminex and Applied Biosystems' TaqMan® technology.